Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells
Brian J. Morrison(Naval Medical Research Command), John C. Morris(University of Cincinnati)
Cited by 131
Related Papers
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
|Frontiers in Oncology|2021|26
Does prior dengue virus exposure worsen clinical outcomes of Zika virus infection? A systematic review, pooled analysis and lessons learned
|PLoS neglected tropical diseases|2019|23
Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
|Journal of Clinical Oncology|2019|8
Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
|Asian Pacific Journal of Cancer Prevention|2019|6